Cited by 122Bipolar Disorder and TreatmentTreatment of Major DepressionSchizophrenia research and treatment

Protein Kinase C Inhibitors: Rationale for Use and Potential in the Treatment of Bipolar Disorder

Open access
Zarate, Carlos A., Manji, Husseini K.·2009·CNS Drugs

Abstract

Bipolar disorder is one of the most severely debilitating of all medical illnesses. For a large number of patients, outcomes are quite poor. The illness results in tremendous suffering for patients and their families and commonly impairs functioning and workplace productivity. Risks of increased morbidity and mortality, unfortunately, are frequent occurrences as well. Until recently, little has been known about the specific molecular and cellular underpinnings of bipolar disorder. Such knowledge is crucial for the prospect of developing specific targeted therapies that are more effective and that have a more rapid onset of action than currently available treatments. Exciting recent data suggest that regulation of certain signalling pathways may be involved in the aetiology of bipolar disorder and that these pathways may be profitably targeted to treat the disorder. In particular, mania is associated with overactive protein kinase C (PKC) intracellular signalling, and recent genome-wide association studies of bipolar disorder have implicated an enzyme that reduces the activation of PKC. Importantly, the current mainstays in the treatment of mania, lithium (a monovalent cation) and valproate (a small fatty acid) indirectly inhibit PKC. In addition, recent clinical studies with the relatively selective PKC inhibitor tamoxifen add support to the relevance of the PKC target in bipolar disorder. Overall, a growing body of work both on a preclinical and clinical level indicates that PKC signalling may play an important role in the pathophysiology and treatment of bipolar disorder. The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2165/00023210-200923070-00003

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [40]Birnbaum SG Yuan PX Wang M Protein kinase C overactivity impairs prefrontal cortical regulation of working memory Science 2004 306 5697 882 4 15514161

Cited by

Sorted by citations

Authors
Zarate, C. A., & Manji, H. K.
Affiliations
  • National Institutes of Health (US)
  • National Institute of Mental Health (US)
Corresponding author
Zarate, Carlos A.
Venue
CNS Drugs
Published
2009-07
Volume
23
Issue
7
Pages
569-582
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2139699538
Cited by
122
References
80
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 7 · 2019: 10 · 2018: 5 · 2017: 13 · 2016: 6 · 2015: 6 · 2014: 10 · 2013: 7 · 2012: 12
FWCI
1.30
Type
journal article
Language
en
Open access
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (Z01MH002830)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
protein kinase C, PKC inhibitors, bipolar disorder, mania, lithium, valproic acid, tamoxifen, targeted therapy, genome-wide association study
MeSH terms
Animals, Bipolar Disorder, Clinical Trials as Topic, Humans, Models, Biological, Protein Kinase C, Antimanic Agents, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review